Eikance 0.01%, the first pharmacotherapy registered on the Australian Register of Therapeutic Goods to slow the progression of myopia in children aged four to 14 years,1# may be initiated in children when myopia progresses ≥-1.0 D per year.1
Eikance 0.01% single-use ampoules are sealed in foil pouches and are available in packs of 30 x 0.3 mL ampoules. The ophthalmic solution is sterile and preservative-free. Eikance 0.01% is a prescription only medicine available at pharmacies across Australia.
Contact: Aspen Pharmaceuticals (AUS) 02 8436 8300
PBS information: This product is not listed on the Pharmaceutical Benefits Scheme (PBS)
Before prescribing, please review the product information.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems.
# Australian Register of Therapeutic Goods. Accessed: 11 March 2024.
Reference
- Eikance approved product information. AU-ATR-032024-08305.
